GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (FRA:0PQ) » Definitions » Cash, Cash Equivalents, Marketable Securities

ProQR Therapeutics NV (FRA:0PQ) Cash, Cash Equivalents, Marketable Securities : €89.40 Mil (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is ProQR Therapeutics NV Cash, Cash Equivalents, Marketable Securities?

ProQR Therapeutics NV's quarterly cash, cash equivalents, marketable securities declined from Mar. 2024 (€102.71 Mil) to Jun. 2024 (€96.15 Mil) but then stayed the same from Jun. 2024 (€96.15 Mil) to Sep. 2024 (€89.40 Mil).

ProQR Therapeutics NV's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (€187.52 Mil) to Dec. 2022 (€94.78 Mil) but then increased from Dec. 2022 (€94.78 Mil) to Dec. 2023 (€118.93 Mil).


ProQR Therapeutics NV Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for ProQR Therapeutics NV's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProQR Therapeutics NV Cash, Cash Equivalents, Marketable Securities Chart

ProQR Therapeutics NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 111.95 75.84 187.52 94.78 118.93

ProQR Therapeutics NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 120.55 118.93 102.71 96.15 89.40

ProQR Therapeutics NV Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


ProQR Therapeutics NV  (FRA:0PQ) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


ProQR Therapeutics NV Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of ProQR Therapeutics NV's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


ProQR Therapeutics NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProQR Therapeutics NV (FRA:0PQ) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

ProQR Therapeutics NV Headlines

No Headlines